Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

May 15, 2023

Welcome to Nicola

Nicola received his B.Sc in Biology from ETH Zürich in 2021. He is currently enrolled in the Molecular Health Sciences Master´s degree at ETH Zürich and joined...

April 21, 2023

Welcome to Naomi!

Naomi received her Bachelor’s degree in Health Science and Technology from ETH Zurich in 2021. Naomi joined the Corn lab in March 2023 as a Master student. For...

March 7, 2023

Congratulations to Mandy on the Innosuisse grant!

Mandy was awarded the Innosuisse Innovation grant to fund her translational work on developing gene therapies for hereditary blood diseases. This grant ...

News Archive

Tweets